RxDoctor Payments Data

Peter Kohler, MD

Ophthalmology · Waterville, MENPI 1417954066

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $838 of the $1,363 with a category attached, or 61.4%. 8 manufacturers reported payments, led by Eyepoint US, Inc. at 36.7% of the total. Reporting peaked in 2020 at $500 and has fallen 58.2% since, to $209 in 2025.

$1,363in general payments, 2019–2025

Across 30 payments — averaging $45.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eyepoint US, Inc.$500
  • Johnson & Johnson Surgical Vision, Inc.$301
  • Alcon$193
  • AbbVie$134
  • Rxsight Inc$113
  • Ivantis, Inc$82
  • plus $41 from 2 others

What the payments were for

  • Consulting fees$50037%
  • Speaking & faculty fees$262%
  • Food & beverage$83861%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,363 in reported general payments places this provider in the 75th percentile of 74 ophthalmology providers in Maine.

See all ophthalmology providers in Maine

Medicare billing

Part B allowed, 2024
$225,243
Medicare patients
432
Services billed
2,186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost82$41,922
Prednisolone Acetate652$25,865
RhopressaNetarsudil Mesylate47$18,310
RestasisCyclosporine11$17,106
Alphagan PBrimonidine Tartrate33$10,057
SimbrinzaBrinzolamide/Brimonidine Tart23$6,380
Brimonidine Tartrate81$6,294
RocklatanNetarsudil Mesylat/Latanoprost11$6,284
CombiganBrimonidine Tartrate/Timolol14$4,549
Travoprost45$4,267
Latanoprost189$2,052
Brinzolamide18$1,966
Timolol Maleate186$1,391
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat42$755
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$134$73,634140 claims
AlconSimbrinza$193$6,38023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 ophthalmology providers in Maine.

Other ophthalmology in Waterville

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →